Cover Image
市場調查報告書

生殖細胞瘤 : 開發平台分析

Germ Cell Tumors - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 213071
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
生殖細胞瘤 : 開發平台分析 Germ Cell Tumors - Pipeline Review, H2 2015
出版日期: 2015年08月26日 內容資訊: 英文 88 Pages
簡介

生殖細胞瘤是惡性(癌性)或是良性(非癌性)腫瘤,主要由生殖細胞所構成。生殖細胞是在胎兒體內發育,構成男性、女性生殖系統的細胞。這些生殖細胞在發育後會通過人體正中線,在骨盆分化為卵子,在精囊分化為精子。卵巢腫瘤·精巢腫瘤幾乎皆由生殖細胞發病。卵巢·精囊又通稱為生殖腺。

本報告提供全球各國治療生殖細胞瘤用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查結果。

簡介

  • 分析範圍

生殖細胞瘤概要

治療藥的開發

  • 生殖細胞瘤開發中產品:概要
  • 生殖細胞瘤開發中產品:比較分析

各企業開發中的生殖細胞瘤治療藥

大學/研究機關研究中的生殖細胞瘤治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

生殖細胞瘤治療藥:開發中的產品一覽(各企業)

生殖細胞瘤治療藥:研究中的產品一覽(大學/研究機關別)

開發治療藥的企業

  • AB Science SA
  • ArQule, Inc.
  • Astex Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • MediGene AG
  • Merck & Co., Inc.
  • Novartis AG
  • Philogen S.p.A.
  • Sanofi

生殖細胞瘤:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • cabazitaxel
  • Cell Therapy 1 for Oncology
  • (dabrafenib mesylate + trametinib dimethyl sulfoxide)
  • G-207
  • guadecitabine
  • pembrolizumab
  • ribociclib
  • Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML
  • Small Molecules to Inhibit Tubulin for Oncology
  • Tetravil
  • tivantinib

生殖細胞瘤治療藥:最新的藥物簡介

生殖細胞瘤治療藥:暫停開發的產品

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7014IDB

Summary

Global Markets Direct's, 'Germ Cell Tumors - Pipeline Review, H2 2015', provides an overview of the Germ Cell Tumors's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Germ Cell Tumors
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Germ Cell Tumors and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Germ Cell Tumors pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Germ Cell Tumors
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Germ Cell Tumors pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Germ Cell Tumors Overview
  • Therapeutics Development
    • Pipeline Products for Germ Cell Tumors - Overview
    • Pipeline Products for Germ Cell Tumors - Comparative Analysis
  • Germ Cell Tumors - Therapeutics under Development by Companies
  • Germ Cell Tumors - Therapeutics under Investigation by Universities/Institutes
  • Germ Cell Tumors - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Germ Cell Tumors - Products under Development by Companies
  • Germ Cell Tumors - Products under Investigation by Universities/Institutes
  • Germ Cell Tumors - Companies Involved in Therapeutics Development
    • AB Science SA
    • ArQule, Inc.
    • Astex Pharmaceuticals, Inc.
    • GlaxoSmithKline Plc
    • MediGene AG
    • Merck & Co., Inc.
    • Novartis AG
    • Philogen S.p.A.
    • Sanofi
  • Germ Cell Tumors - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cabazitaxel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • G-207 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • guadecitabine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ribociclib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Tubulin for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Tetravil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tivantinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Germ Cell Tumors - Recent Pipeline Updates
  • Germ Cell Tumors - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Germ Cell Tumors, H2 2015
  • Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Germ Cell Tumors - Pipeline by AB Science SA, H2 2015
  • Germ Cell Tumors - Pipeline by ArQule, Inc., H2 2015
  • Germ Cell Tumors - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
  • Germ Cell Tumors - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Germ Cell Tumors - Pipeline by MediGene AG, H2 2015
  • Germ Cell Tumors - Pipeline by Merck & Co., Inc., H2 2015
  • Germ Cell Tumors - Pipeline by Novartis AG, H2 2015
  • Germ Cell Tumors - Pipeline by Philogen S.p.A., H2 2015
  • Germ Cell Tumors - Pipeline by Sanofi, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Germ Cell Tumors Therapeutics - Recent Pipeline Updates, H2 2015
  • Germ Cell Tumors - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Germ Cell Tumors, H2 2015
  • Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top